NYSESYK

Stryker: Mako Shoulder And Spine Launches Are On The Way (NYSE:SYK)

admin5 months ago08 mins

gorodenkoff I initiated Stryker (NYSE:SYK) in August 2023, and pointed out that Mako would continue to be a growth driver for the company. They reported a strong Q3 FY23 result and provided an initial FY24 guidance with 10%+ organic revenue growth. The Mako shoulder and spine applications are on track, and I think they are…

Stryker: Cash Flow Returns On Investments Analysis (NYSE:SYK)

admin9 months ago013 mins

jitendrajadhav/iStock via Getty Images We are initiating Stryker (NYSE:SYK) with a hold rating. This is a high-quality company with a solid history of growth, high margins, and stable returns. However, we believe the company is slightly overvalued, and better opportunities exist elsewhere. We recently wrote about other healthcare companies that seem to be offering better…

Enbridge: Preferred Shares Most Resilient In Bond Bear Market (OTCMKTS:EBBGF)

Albertsons May Be Win-Win Proposition, With Or Without Kroger Deal (NYSE:ACI)

Philip Morris: Long-Term Looks Good, Short-Term Upside Exhausted (NYSE:PM)

CSQ: Impressive Track Record But Not Impressively Priced (NASDAQ:CSQ)

Gladstone Investment: Drop in Dividend Coverage Not A Reason To Sell (NASDAQ:GAIN)

S&P 500: Too Easy, Week Starting 20th May (Technical Analysis) (SP500)

Stryker: Mako Shoulder And Spine Launches Are On The Way (NYSE:SYK)

Stryker: Cash Flow Returns On Investments Analysis (NYSE:SYK)